%0 Journal Article
%T Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus
%A Daisuke Suzuki
%A Hirohisa Tsuchiya
%A Hiroshi Shigematsu
%A Hirosuke Danno
%A Mari Oba
%A Mizuki Kaneshiro
%A Tadashi Yamakawa
%A Yasuo Terauchi
%A Yoji Takatsuka
%A Yukari Chiba
%J Journal of Clinical Medicine Research
%D 2018
%R https://doi.org/10.14740/jocmr3464w
%X Background: Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor expected to improve the lipid profile as well as glycemic control. However, findings from large-scale prospective trials have not been obtained.
%U https://www.jocmr.org/index.php/JOCMR/article/view/3464